Multiple Myeloma Treatments
Below are links to information from the National Cancer Institute (NCI) about FDA-approved, commonly used medications for the treatment of multiple myeloma. NCI also has an extensive list of multiple myeloma meds, including many older drugs.
(Maybe the best feature is that the NCI site pronounces the name of the drug for you :) )
- Abecma (idecabtagene vicleucel, ida cel) (Cell-Based Gene Therapy, CAR-T)
- Alkeran (melphalan)
- Aredia (pamidronate disodium) (Bisphosphonate, used to treat bone disease, not myeloma itself)
- Blenrep (belantamab mafodotin) (Antibody Drug Conjugate) Note: GSK pulls Blenrep from the US market on Nov. 22, 2022 due to DREAMM-3 clinical trial results
- Carvykti (ciltacabtagene autoleucel, cilta cel) (Cell-Based Gene Therapy, CAR-T)
- Cytoxan (cyclophosphamide) (Alkylating Agent)
- Darzalex (daratumumab) (Monoclonal Antibody)
- Darzalex Faspro (daratumumab and hyaluronidase) (Monoclonal Antibody)
- Decadron (dexamethasone) (Corticosteroid)
- Elrexfio (elranatamab-bcmm) (Bi-Specific T-Cell Engager)
- Empliciti (elotuzumab) (Monoclonal Antibody)
- Farydak (panobinostat) (Histone Deacetylase (HDAC) Inhibitor) NOTE: FDA withdrew this drug's approval in Nov., 2021
- Kyprolis (carfilzomib) (Proteasome Inhibitor)
- Ninlaro (ixazomib citrate) (Proteasome Inhibitor)
- Pomalyst (pomalidomide) (Immunomodulatory Agent)
- Rayos (prednisone) (Corticosteroid)
- Revlimid (lenalidomide) (Immunomodulatory Agent)
- Sarclisa (isatuximab) (Monoclonal Antibody)
- Talvey (talquetamab-tgvs) (Bi-Specific T-Cell Engager)
- Tecvayli (teclistamab) (Bi-Specific T-Cell Engager)
- Thalomid (thalidomide) (Immunomodulatory Agent)
- Velcade (bortezomib) (Proteasome Inhibitor)
- Xgeva (denosumab) (Monoclonal Antibody, used in some cases to treat bone disease instead of bisphosphonates)
- Xpovio (selinexor) (Selective Inhibitor of Nuclear Export / Chromosome Region Maintenance 1 Protein (CRM1) Inhibitor)
- Zometa (zoledronic acid) (Bisphosphonate, used to treat bone disease, not myeloma itself)